Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.30 |
| ▸ | TUBB | P07437 | 1/20 | 0.30 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.30 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.30 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.30 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.30 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.30 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.30 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.30 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.30 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.30 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.30 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.30 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.30 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725762 | 0.86 | BRD4 (0.33) | METAP2BRD4 | |
| SCHEMBL24786481 | 0.75 | BRD4 (0.35) | METAP2BRD4 | |
| SCHEMBL20577534 | 0.74 | AXL (0.37) | METAP2BRD4 | |
| SCHEMBL24613002 | 0.71 | BRD4 (0.33) | METAP2BRD4 | |
| SCHEMBL25241637 | 0.68 | AXL (0.37) | METAP2BRD4 | |
| SCHEMBL24841969 | 0.67 | METAP2 (0.36) | METAP2 | |
| SCHEMBL25581727 | 0.67 | TSHR (0.36) | — | |
| SCHEMBL26077501 | 0.66 | METAP2 (0.35) | METAP2 | |
| SCHEMBL29285140 | 0.66 | LMNA (0.40) | METAP2BRD4 | |
| SCHEMBL24841970 | 0.66 | KDM4E (0.37) | METAP2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | METAP2 1395/4885BRD4 4666/4885TUBB4A 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.